ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform
26 Junio 2023 - 6:15AM
Business Wire
Latest features support greater patient
centricity and speed in study start-up
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence
and clinical research organisation, today announced the latest
release of its Digital Platform. The platform supports seamless
integration of ICON patient, site and sponsor services with the
delivery of harmonised data and can be customised for any study
design, from traditional to fully decentralised, and for any
therapeutic area.
The ICON Digital Platform is an end-to-end solution that enables
patient services throughout clinical trials including an
easy-to-use patient mobile app, eConsent, eCOA, direct data capture
for in-home services, televisits and digital health technology
management. It offers the technical functionality, standard
capability and integrated services, in one platform, that enable
flexibility for any clinical trial.
Features of the ICON Digital Platform include the eCOA module
which is pre-loaded with the validated Mapi Research Trust library,
instruments and translations, reducing eCOA set-up during study
start-up. It also supports the seamless integration of the
FIRECREST Site Portal for training and communications, Clinical
Trial Tokenisation, digital outreach for patient recruitment and
laboratory data, along with reporting dashboards and analytics.
Connecting and engaging patients in decentralised clinical
trials is of increasing importance and ICON offers a wide range of
customised, clinical and technical Concierge Services to support
users of the Digital Platform including enrolment and on-boarding,
technology and device logistics support, adherence check-ins and
study completion services.
The platform deployment and management are governed by ICON’s
robust regulatory framework, and this, along with its global
scalability capabilities, including language localisation, reduces
regulatory compliance risk for sponsors.
Steve Cutler, CEO, ICON, commented: “This newest version of the
Digital Platform enables the efficient capture and delivery of
quality data from a range of decentralised clinical trial services.
Its ease of use enables greater patient centricity, reducing the
barriers to trial participation and enhancing the equity, diversity
and inclusion of patient populations.”
Built on a scalable cloud-first framework, API first
architecture, this modular and fully configurable platform reduces
deployment and study start-up timelines and enables
interoperability of key operational systems.
For further information the ICON Digital Platform please visit
www.iconplc.com/digital-platform.
Ends
This press release contains forward-looking statements,
including statements about our financial guidance. These statements
are based on management's current expectations and information
currently available, including current economic and industry
conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, the impact of
COVID-19 on our business, as well as other economic and global
market conditions and other risks and uncertainties detailed from
time to time in SEC reports filed by ICON, all of which are
difficult to predict and some of which are beyond our control. For
these reasons, you should not place undue reliance on these
forward-looking statements when making investment decisions. The
word "expected" and variations of such words and similar
expressions are intended to identify forward-looking statements.
Forward-looking statements are only as of the date they are made
and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information,
future events or otherwise. More information about the risks and
uncertainties relating to these forward-looking statements may be
found in SEC reports filed by ICON, including its Form 20-F, F-1,
F-4, S-8, F-3 and certain other reports, which are available on the
SEC's website at http://www.sec.gov.
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical
research organisation. From molecule to medicine, we advance
clinical research providing outsourced services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. We develop new innovations, drive emerging therapies
forward and improve patient lives. With headquarters in Dublin,
Ireland, ICON employed approximately 41,150 employees in 109
locations in 53 countries as at March 31, 2023. For further
information about ICON, visit: www.iconplc.com.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230626238713/en/
Media contacts:
Claire Quinn Corporate Communications, ICON +353 87 4066091
claire.quinn@iconplc.com
Weber Shandwick (PR adviser) Lisa Henry +44 7785 458203
lhenry@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ICON (NASDAQ:ICLR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024